WallStSmart

Becton Dickinson and Company (BDX)vsMilestone Scientific (MLSS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 245423% more annual revenue ($21.92B vs $8.93M). BDX leads profitability with a 8.0% profit margin vs -74.7%. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

MLSS

Avoid

16

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -18.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued

Intrinsic value data unavailable for MLSS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

MLSS0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

MLSS4 concerns · Avg: 3.3/10
Price/BookValuation
10.0x4/10

Trading at 10.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$22.57M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-136.5%2/10

ROE of -136.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : MLSS

MLSS has a balanced fundamental profile.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : MLSS

The primary concerns for MLSS are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

BDX profiles as a value stock while MLSS is a turnaround play — different risk/reward profiles.

MLSS carries more volatility with a beta of 0.94 — expect wider price swings.

BDX is growing revenue faster at 1.6% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (61/100 vs 16/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Milestone Scientific

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Milestone Scientific, Inc. develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company is headquartered in Livingston, New Jersey.

Visit Website →

Want to dig deeper into these stocks?